Treatment Strategies for Myeloid Growth Factors and Intravenous Iron: When, What, and How?

Authors: Jeffrey Crawford MD 1 and George M. Rodgers MD, PhD 1
View More View Less
  • 1 Presented by Jeffrey Crawford, MD, Chief, Division of Medical Oncology, Professor of Medicine, Duke Cancer Institute, Durham, North Carolina, and George M. Rodgers, MD, PhD, Professor of Medicine, Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah.
Restricted access

Myeloid growth factors can reduce the risk of chemotherapy-induced neutropenia (CIN) and thus impact the survival of patients with cancer. Patients should be assessed for risk, taking into consideration patient-related risk factors and chemotherapy regimens. Patients stratified as having at least a 20% risk for CIN should be considered for prophylactic growth factors. The NCCN Guidelines for Myeloid Growth Factors provide category 1 recommendations for the daily use of filgrastim, tbo-filgrastim, and pegfilgrastim. Cancer-related anemia can be treated with erythropoiesis-stimulating agents, red blood cell transfusion, or intravenous iron.

Correspondence: Jeffrey Crawford, MD, Duke Cancer Institute, Duke University Medical Center, 441 Seeley G. Mudd Building, 10 Bryan Searle Drive, Box 3476, Durham, NC 27710. E-mail: crawf006@mc.duke.eduCorrespondence: George M. Rodgers, MD, PhD, Huntsman Cancer Institute at the University of Utah, Division of Hematology, University of Utah Medical Center, 30 North 1900 East, Rm 5C-402, Salt Lake City, UT 84132. E-mail:
  • 1.

    Kuderer NM, Dale DC, Crawford J. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006;106:22582266.

    • Search Google Scholar
    • Export Citation
  • 2.

    Hirsch BR, Lyman GH. Will biosimilars gain momentum? J Natl Compr Canc Netw 2013;11:12911297.

  • 3.

    Lyman GH, Kuderer NM, Crawford J. Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer 2011;117:19171927.

    • Search Google Scholar
    • Export Citation
  • 4.

    Gilreath JA, Stenehjem DD, Rodgers GM. Diagnosis and treatment of cancer-related anemia. Am J Hematol 2014;89:203212.

  • 5.

    Gilreath JA, Sajeser DS, Jorgenson JA, Rodgers GM. Establishing an anemia clinic for optimal erythropoietic-stimulating agent use in hematology-oncology patients. J Natl Compr Canc Netw 2008;6:577584.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 138 116 13
PDF Downloads 29 21 0
EPUB Downloads 0 0 0